新辅助化疗对胃癌患者术后早期疼痛及围术期恢复的影响-东南大学学报医学版

新辅助化疗对胃癌患者术后早期疼痛及围术期恢复的影响

单位：南京中医药大学附属医院麻醉科, 江苏南京 210029

分类号：R735.2

出版年·卷·期（页码）：2020·39·第六期（716-720）

摘要：

目的：探讨新辅助化疗对进展期胃癌患者术后早期疼痛及围术期恢复的影响。方法：采用回顾性分析方法，收集2017年1月至2018年12月进展期胃癌且行胃癌根治术患者74例的临床资料，患者年龄≥18岁，ASA Ⅱ~Ⅲ级。根据是否接受新辅助化疗将患者分为新辅助化疗组（N组，35例）和对照组（C组，39例）。N组患者接受FOLFOX方案化疗，化疗结束后2周行胃癌根治术，两组患者麻醉方案相同。记录两组患者一般情况、气管导管拔出时间、麻醉后恢复室（PACU）停留时间、术后几个时间点（6、24、48、72 h）疼痛数字评价量表（NRS）评分、补救性镇痛药使用例数、术后住院时间及不良反应。结果：与C组相比，N组患者术后24、48、72 h NRS评分均增高，气管导管拔出时间延长，PACU停留时间延长，术后补救性镇痛药使用例数增多，术后住院时间延长（均P<0.05）；两组患者术后首次排便及不良反应发生率比较差异无统计学意义（P>0.05）。结论：新辅助化疗可增加胃癌根治术患者术后早期的疼痛强度和镇痛药的使用，延长气管导管拔出时间、PACU停留时间及术后住院时间，但不增加相关不良反应。

Objective: To investigate the effect of neoadjuvant chemotherapy on early postoperative pain and perioperative recovery in patients with advanced gastric cancer. Methods: A retrospective analysis method was used to collect clinical data of patients with advanced gastric cancer who underwent radical gastric cancer surgery between January 2017 and December 2018. A total of 74 patients aged 18 years or more with ASA grade Ⅱ-Ⅲ were enrolled. According to whether the patients received neoadjuvant chemotherapy, they were divided into the neoadjuvant chemotherapy group(group N, n=35) and the control group(group C, n=39). Patients in group N received FOLFOX chemotherapy, and radical gastric cancer surgery was performed 2 weeks after chemotherapy. The two groups of patients received identical anesthesia plans. We recorded the general conditions of the patients, time of tracheal extubation, time of stay in the postanaesthesia care unit(PACU), 6, 24, 48, 72 h postoperative pain numerical rating scale, number of cases of rescue analgesics, length of postoperative hospital stay and adverse reactions. Results: Compared with patients in group C, patients in group N had significantly higher NRS at 24 h, 48 h, and 72 h after surgery, longer time of tracheal extubation, longer PACU stay time, larger numbers of postoperative rescue analgesics, and longer postoperative hospital stays(all P<0.05). There was no significant difference in the time of initial postoperative defecation and the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Neoadjuvant chemotherapy can increase the pain intensity and the use of analgesics in the early postoperative period of radical gastric cancer patients, prolong the tracheal tube extraction time, PACU stay time and the postoperative hospital stay, but does not increase related adverse reactions.

参考文献：

[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[2] WAMG T T,ZHAO Y L,PENG L S,et al.Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway[J].Gut,2017,66(11):1900-1911.
[3] ALLEMANI C,MATSUDA T,DI CARLO V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
[4] WANG L B,SHEN J G,XU C Y,et al.Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer:a retrospective comparative study[J].Hepato Gastroenterology,2008,55(86-87):1895-1898.
[5] TAILLIBERT S,LE RHUN E,CHAMBERLAIN M C.Chemotherapy-related nurotoxicity[J].Curr Neurol Neurosci Rep,2016,16(9):81.
[6] LOPRINZI C L,REEVES B N,DAKHIL S R,et al.Natural history of paclitaxel-associated acute pain syndrome:prospective cohort study NCCTG N08CI[J].J Clin Onco1,2011,29(11):1472-1478.
[7] FUSE N,DOI T,OHTSU A,et al.Feasibility of oxaliplatin and infusionalfluorouracil/leucovorin(FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer[J].Jpn J Clin Oncol,2007,37(6):434-439.
[8] GANESH YERRA V,NEGI G,SHARMA S S,et al.Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-KB pathways in diabetic neuropathy[J].Redox Biol,2013,1(1):394-397.
[9] SCHREIBER K L,KEHLET H,BELFER I,et al.Predicting,preventing and managing persistent pain after breast cancer surgery:the importance of psychosocial factors[J].Pain Manag,2014,4(6):445-459.
[10] SCHUHMACHER C P,FINK U,BECKER K,et al.Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide,doxorubicin,and cisplatinum.Closing results after 5 years of follow-up[J].Cancer,2001,91(5):918-927.
[11] SMITH E M,COHEN J A,PETT M A,et al.The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums[J].Cancer Nurs,2010,33(3):173-183.
[12] CHENG X L,LIU H Q,WANG Q,et al.Chemotherapy-induced peripheral neurotoxity and complementary and alternative medicines:progress and perspective[J].Front Pharmacol,2015,6:234.
[13] JACOBS S,MCCULLY C L,MURPHY R F,et al.Extracellular fluid concentrations of cisplatin,carboplatin,and oxaliplatin in brain,muscle,and blood measured using microdialysis in nonhuman primates[J].Cancer Chemother Pharmacol,2010,65(5):817-824.
[14] XIAO W H,ZHENG H,BENNETT G J.Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel[J].Neuroscience,2012,203:194-206.
[15] CHAPMAN C R,TUCKETT P R,SONG C W.Pain and stress in a systems perspective:reciprocal neural,endocrine,and immune interactions[J].J Pain,2008,9(2):122-145.
[16] SWANSON H I,NJAR V C,YU Z,et al.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy[J].Drug Metab Dispos,2010,38(4):539-544.
[17] YANG R,HAN J L,ZHANG W M,et al.Effect of neoadjuvant chemotherapy on local advanced esophageal cancer[J].Chin J Clin Oncol,2014,41(2):119-122.
[18] 郭亮,林飞,于美钢,等.奥沙利铂术前化疗对老年胃肠道肿瘤患者术后认知功能障碍的影响[J].中国癌症防治杂志,2018,10(4):209-304.
[19] GAFTER-GVILI A,POLLIACK A.Bendamustine associated immune suppression and infections during therapy of hematological malignancies[J].Leuk Lymphoma,2016,57(3):512-519.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录